Veracyte Q1 2024 GAAP EPS $(0.02) Beats $(0.17) Estimate, Sales $96.844M Beat $93.370M Estimate
Veracyte Q1 2024 GAAP EPS $(0.02) Beats $(0.17) Estimate, Sales $96.844M Beat $93.370M Estimate
Veracyte 2024 年第一季度的 GAAP 每股收益 (0.02) 超过预期 (0.17) 美元，销售额为 9,684.4 万美元超过预期 9,3370 万美元
Veracyte (NASDAQ:VCYT) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.17) by 88.24 percent. This is a 81.82 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $96.844 million which beat the analyst consensus estimate of $93.370 million by 3.72 percent. This is a 17.50 percent increase over sales of $82.422 million the same period last year.
Veracyte（纳斯达克股票代码：VCYT）公布的季度亏损为每股0.02美元，比分析师普遍预期的0.17美元（0.17美元）高出88.24％。这比去年同期每股亏损0.11美元（0.11美元）增长了81.82％。该公司公布的季度销售额为9,684.4万美元，比分析师普遍预期的9,3370万美元高出3.72％。这比去年同期的8242.2万美元的销售额增长了17.50％。